Riley Elmer
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Readiness potential as a neural correlate of motor planning in toddlers and young children
Open Date:
Close Date:
Articles (17)
Year:
2024
Supplementary Figure S2 shows the classification of MTG001 and MTG004. Immunoblotting of MTG001 and MTG004 PDX-derived cell lines showed similar levels of P-AKT (Ser473), total AKT, P-ERK (Thr202/Tyr204), ERK1/2, P-Ribosomal S6 Kinase (Ser235/236), and S6 Kinase. GAPDH was used as a loading control. The MTG001 cells exhibited higher levels of total PTEN. Analysis of RNA sequencing data demonstrated that both MTG001 and MTG004 express wildtype PTEN.
Year:
2024
Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo . Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.
Year:
2024
Supplementary Figure S7 shows chemical structures of all pharmacological agents utilized in study, including MK2206, GSK2141795, GDC-0941, BYL719, RapaLink-1, GSK650394, GDC-0068, GDC-0084, and INY-03-041.
Year:
2024
Supplementary Figure S1 shows that pharmacological inhibition of AKT has little effect on melanoma cells. Cell confluency assay under pharmacological inhibition. A375, HT144, SK-MEL28, WM793, MTG001, and MTG004 cells were largely resistant to AKT inhibitors MK2206 (2.5 µM) and GDC0068 (1µM) while A375, HT144, WM793, SK-MEL 28 and MTG001 cells were largely sensitive to PI3Kα inhibition by GDC0941 (1µM) (P
Year:
2024
Supplementary Figure S6 shows that INY-03-041 leads to a substantial effect on melanoma cell proliferation but it is not as potent as siAKT1-3. A, Cell confluency assay of MTG001 and MTG004 cell lines treated with DMSO control, GDC0068 (1µM), INY-03-041 (1µM), GDC0941 (1µM), Lenalidomide (1µM), or siAKT1-3 (50nM). Treatment with INY-03-041 led to decreased cell proliferation (P
Year:
2024
Supplementary Figure S4 demonstrates that siAKT1-3 is specific for human AKT. A, The cell confluency assay of YUMM1.1 mouse melanoma cells under genetic inhibition demonstrated no effect on cell death with siAKT1, siAKT2, siAKT3, or any combination. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of YUMM1.1 cells treated with siCtrl vs siAKT1-3. No knockdown of P-AKT (Ser473) or P-PRAS40 (T246) indicated the specificity of the siRNAs for human AKT.
Year:
2024
Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo . Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.
Year:
2024
Supplemental Figure 5 shows that caspase 3 and 8 inhibition protects melanoma cells from siAKT1-3-mediated apoptosis. A, Cell confluency assay upon treatment with siAKT1-3 versus co-treatment with caspase inhibitors. Co-treatment of A375 and MTG004 cells with Z-VAD-FMK, Z-DEVD-FMK, and Z-IETD-FMK inhibitors protected cells against siAKT1-3-mediated cell death. B, Incuycte® Cytotox Red assay comparing siCtrl, siAKT1-3, siCtrl + each caspase inhibitor, and siAKT1-3 + caspase inhibitors. C, Incuycte® Caspase 3/7 assay comparing siCtrl, siAKT1-3, siCtrl + each caspase inhibitor, and siAKT1-3 + caspase inhibitors. The percentage of dead cells stained with Cytotox red and caspase 3/7 reagents increased only in the siAKT1-3 group, indicating complete rescue with caspase 3, 8, or pan inhibition.
Year:
2024
Supplementary Figure S2 shows the classification of MTG001 and MTG004. Immunoblotting of MTG001 and MTG004 PDX-derived cell lines showed similar levels of P-AKT (Ser473), total AKT, P-ERK (Thr202/Tyr204), ERK1/2, P-Ribosomal S6 Kinase (Ser235/236), and S6 Kinase. GAPDH was used as a loading control. The MTG001 cells exhibited higher levels of total PTEN. Analysis of RNA sequencing data demonstrated that both MTG001 and MTG004 express wildtype PTEN.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (5)
Robert Judson‐Torres
-
Gennie Parkman
Assistant Professor
Weber State University
Sheri L. Holmen
Professor
University of Utah Health Sciences Center
Martin McMahon
Cumming-Presidential Chair of Cancer Biology
University of Utah
Kayla O'Toole
University of Utah
Make your next move.
Prepare your application
Review drafts before you send them.